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Abstract
Objective—Cyclooxygenase-1 (COX-1, PTGS1) catalyzes the conversion of arachidonic acid to
prostaglandin H2, which is subsequently metabolized to various biologically active prostaglandins.
We sought to identify and characterize the functional relevance of genetic polymorphisms in
PTGS1.
Methods—Sequence variations in human PTGS1 were identified by resequencing 92 healthy
individuals (24 African, 24 Asian, 24 European/Caucasian, and 20 anonymous). Using site-directed
mutagenesis and a baculovirus/insect cell expression system, recombinant wild-type COX-1 and the
R8W, P17L, R53H, R78W, K185T, G230S, L237M, and V481I variant proteins were expressed.
COX-1 metabolic activity was evaluated in vitro using an oxygen consumption assay under basal
conditions and in the presence of indomethacin.
Results—Forty-five variants were identified, including seven nonsynonymous polymorphisms
encoding amino acid substitutions in the COX-1 protein. The R53H (35 ± 5%), R78W (36 ± 4%),
K185T (59 ± 6%), G230S (57 ± 4%), and L237M (51 ± 3%) variant proteins had significantly lower
metabolic activity relative to wild-type (100 ± 7%), while no significant differences were observed
with the R8W (104 ± 10%), P17L (113 ± 7%), and V481I (121 ± 10%) variants. Inhibition studies
with indomethacin demonstrated that the P17L and G230S variants had significantly lower IC50
values compared to wild-type, suggesting these variants significantly increase COX-1 sensitivity to
indomethacin inhibition. Consistent with the metabolic activity data, protein modeling suggested the
G230S variant may disrupt the active conformation of COX-1.
Conclusions—Our findings demonstrate that several genetic variants in human COX-1
significantly alter basal COX-1-mediated arachidonic acid metabolism and indomethacin-mediated
inhibition of COX-1 activity in vitro. Future studies characterizing the functional impact of these
variants in vivo are warranted.
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Introduction
Cyclooxygenases (COX)-1 and COX-2 catalyze the oxidative conversion of arachidonic acid
to prostaglandin (PG) H2, which is subsequently metabolized to various biologically active
metabolites such as prostacyclin and thromboxane A2 [1]. Although both COX-1 and COX-2
catalyze the same metabolic reaction with similar efficiencies, they are encoded by distinct
gene products and differ substantially in their regulation and expression [1].
The gene encoding human COX-1 (PTGS1) has been mapped to chromosome 9q32–q33.3, is
approximately 22 kb in length, and contains 11 exons [2,3]. COX-1 is constitutively expressed
and is responsible for the biosynthesis of PGs involved in various housekeeping functions,
such as the regulation of renal, gastrointestinal, and platelet function [1]. COX-2 (PTGS2) is
induced by multiple biological mediators, and primarily catalyzes PG synthesis in cells
involved in both local and systemic inflammatory responses [1]. Nonsteroidal anti-
inflammatory drugs (NSAIDs) inhibit COX-mediated PG synthesis and are widely used for
the prevention and/or treatment of various diseases [4]. As a therapeutic class, these agents
demonstrate a wide range of relative selectivity for COX-1 and COX-2, and significant
interindividual variability in clinical response exists [4]. Owing to the inducible nature of
COX-2 regulation and its potential role in the pathogenesis of various inflammatory disorders,
the overwhelming majority of research characterizing the role of COXs in human disease to
date has focused on COX-2. Recent evidence, however, including associations between
selective COX-2 inhibitor utilization and myocardial infarction risk, suggests the relative
contribution of COX-1 and COX-2-mediated PG synthesis is important [5,6]. Consequently,
genetic variation in both PTGS1 and PTGS2 may be important modifiers of disease risk in
humans.
The identification and functional characterization of genetic polymorphisms in PTGS2 have
been reported [7,8]. These studies demonstrate that certain variants significantly alter COX-2
expression and/or activity, and may be important risk factors for disease in humans [7-9]. In
contrast, characterization of genetic variation in PTGS1 has not been as widely investigated,
even though the presence of functionally relevant variants may significantly influence PG
biosynthesis, disease risk, and NSAID pharmacodynamics in humans. Polymorphisms in both
coding and noncoding regions of human PTGS1 have been previously identified [10-13], and
PTGS1 has been resequenced as part of the Seattle SNPs Variation Discovery Resource (http://
pga.mbt.washington.edu/). In particular, nonsynonymous variants encoding amino-acid
substitutions in the COX-1 protein have been identified [10-13]. The functional consequences
of these variants, in terms of their influence on basal COX-1-mediated arachidonic acid
metabolism, however, have not been characterized to date. Human studies have evaluated the
potential influence of certain variants on NSAID-mediated inhibition of COX metabolism in
vivo and ex vivo [12,14-16]; however, the functional consequences of most variants on NSAID
pharmacodynamics are not well understood. Our primary objectives were to: (i) identify or
confirm the existence of polymorphisms in PTGS1 by resequencing, (ii) characterize the
linkage disequilibrium (LD) structure in PTGS1, and (iii) evaluate the functional consequences
of selected variants using established in-vitro assays.
Lee et al. Page 2















All chemicals were purchased from Sigma (St Louis, Missouri, USA), unless otherwise noted.
DNA samples
Genomic DNA was extracted from 72 human lymphoblastoid cell lines (Coriell Institute,
Camden, New Jersey, USA) obtained from healthy individuals with the following ancestries:
24 Africans (16 African-Americans, eight African Pygmy), 24 Asians (five Indo-Pakistani,
five native Taiwanese, five mainland Chinese, three Cambodian, three Japanese, three
Melanesian), 24 European/Caucasians (nine European-Americans, five Druze, five Adygei,
five Russian), and an additional 20 anonymous healthy US residents (DNA Polymorphism
Discovery Resource, NIH) [17], as part of the NIEHS Environmental Genome Single
Nucleotide Polymorphism (egSNP) program (http://dir-apps.niehs.nih.gov/egsnp/home.htm)
[7,18-20].
Genotyping
A resequencing strategy was used to identify variants in both coding and noncoding regions
of PTGS1. Sequencing spanned all 11 exons, including approximately 75 bp 3′ and 5′ of each
intron–exon boundary, and 2.4 kb into the 5′-untranslated region (5′UTR). Amplified
polymerase chain reaction products containing these regions were generated using
oligonucleotide primers specific to PTGS1 (Table 1). All sequencing was performed in both
directions as previously described [7,18-20]. As all DNA samples came from commercially
available cell lines, this protocol was considered exempt by the Lawrence Livermore National
Laboratory Institutional Review Board.
Linkage disequilibrium statistics
Minor allele frequencies and pairwise LD statistics were calculated for each polymorphism,
and the corresponding LD plots were generated (Haploview 3.2, Broad Institute of Harvard
and MIT, Cambridge, Massachusetts, USA) [21]. All analyses were completed independently
in the African, Asian, and European/Caucasian ethnic groups.
Evaluation of COX-1 gene and protein sequences
We extracted approximately 1.8 kb of the human PTGS1 5′UTR sequence from the University
of California Santa Cruz Genome Browser (http://genome.ucsc.edu/), and aligned the
corresponding human, mouse, rat, dog, and chimp sequences for this region to screen for
nucleotide conservation across species at each of the polymorphic sites. We then evaluated the
sequences surrounding each polymorphism for potential location within putative transcription
factor binding sites using the TRANSFAC database [22].
The human, rat, mouse, and sheep COX-1 amino-acid sequences were obtained from Genbank
(U.S. National Library of Medicine, Bethesda, Maryland, USA) and aligned using the ClustalW
program [23] to determine whether the identified nonsynonymous polymorphisms occurred in
conserved regions of the protein. A model of the human COX-1 protein was constructed based
on the ovine COX-1 crystal structure (PDB accession 1Q4G) [24], which has 96% sequence
identity to human COX-1. The model was also compared with the murine COX-2 crystal
structure (PDB accession 1CVU) [25,26]. Additional crystallographic refinement was
performed for both structures using the deposited diffraction data after analysis by MolProbity
(Duke University, Durham, North Carolina, USA) [27]. In both cases, the crystallographic R-
factor was reduced by more than 1% in working and test reflection sets. The procedure for
modeling human COX-1 from the refined ovine structure consisted primarily of selecting
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preferred rotamers [27]. The high level of sequence conservation and lack of insertions or
deletions eliminated the need for changes to the C-α backbone coordinates. Substitution of side
chains using common side-chain rotamers produced an acceptable fit in all cases, so no energy
minimization was performed. To predict the potential impact of amino-acid substitutions on
the structure and function of the COX-1 protein, the R53H, R78W, K185T, G230S, L237M,
and V481I variant amino acids were individually built into the wild-type (WT) human COX-1
model. As the R8W and P17L polymorphisms occur in the COX-1 signal peptide and the ovine
COX-1 crystal structure starts at amino-acid residue 25 [24], the impact of these variants was
not evaluated in the model.
Plasmid construction and site-directed mutagenesis
The full-length COX-1 cDNA was subcloned into pcDNA3.1 (Invitrogen, Carlsbad,
California, USA), as previously described [28]. Single nucleotide polymorphisms (SNPs) were
introduced into the WT COX-1 cDNA by site-directed mutagenesis using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California, USA) as per the manufacturer's
instructions. The specific primer sequences used to generate each of the eight mutations are
provided in Table 2. Presence of the desired mutation in each ampicillin-resistant clone was
confirmed by sequencing the entire COX-1 cDNA using the BigDye Terminator Reaction
Ready Mix (Applied Biosystems, Foster City, California, USA) and ABI Prism 377 DNA
sequencer (Applied Biosystems). WTand variant cDNAs with the desired substitutions and no
secondary mutations were then subcloned into the BamHI/NotI sites of the pVL1393
Baculovirus Transfer Vector (BD Biosciences, San Diego, California, USA) via the
intermediate pCR Blunt II-TOPO vector (Invitrogen). The orientation and sequence of the WT
and variant cDNAs in pVL1393 were confirmed by direct sequencing.
Expression of human COX-1 in Sf9 cells
Sf9 cells were plated in T-25 tissue culture flasks at 2 × 106 cells/flask, cotransfected with 0.5
μg of BaculoGold Bright linearized baculovirus DNA (BD Biosciences) and 2 μg of pVL1393
containing the COX-1 inserts, and incubated at 271C for 96 h. Recombinant baculovirus was
amplified by infecting 50 ml of Sf9 cells (70% confluent) in HyQ SFX-Insect cell culture media
(Fisher Chemical, Fairlawn, New Jersey, USA) and 5% fetal bovine serum with 1 ml of the
transfection supernatant, and incubated in spinner flasks for 72 h at 27°C at 120 r.p.m. Cells
were harvested and lysed by sonication in 80 mmol/l Tris, 2 mmol/l ethylenediaminetetraacetic
acid (EDTA) buffer (pH = 7.2). Viral amplification was qualitatively confirmed by visualizing
green fluorescent protein fluorescence in the lysed cells under ultraviolet light. Uninfected
negative control cells demonstrated no fluorescence. For large-scale COX-1 expression, 1000
ml of Sf9 cells (70% confluent) were infected with each amplification supernatant and
incubated for 72 h in spinner flasks at 27°C at 120 r.p.m., as described [7,29,30]. Cells were
centrifuged for 20 min at 4°C at 3000 r.p.m., washed with ice-cold phosphate-buffered saline,
and centrifuged again. Cell pellets were stored at −80°C after removal of the supernatant.
Cell pellets were thawed on ice and lysed by sonication in an 80 mmol/l Tris, 2 mmol/l EDTA
buffer (pH = 7.2) containing 0.1 mol/l silver diethyldithiocarbamate and protease inhibitors,
as described [7,29,30]. Cell lysates were ultracentrifuged at 40 000 r.p.m. at 4°C for 1 h, and
the microsomal pellets were homogenized in a 200 mmol/l Tris, 0.1 mmol/l EDTA buffer (pH
= 8.0) containing 0.4% CHAPS. Homogenates were stirred for 1.5 h at 4°C while bringing the
final volume to 1% CHAPS (w/v), and ultracentrifuged at 40 000 r.p.m. at 4°C for 45 min.
Supernatants, which contained the solubilized COX-1 enzyme, were stored in aliquots at −80°
C.
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Protein concentrations of the solubilized microsomal fractions were quantified using the Bio-
Rad protein assay (Bio-Rad, Hercules, California, USA). Protein normalized samples were
added to 4× sample buffer containing β-mercaptoethanol and boiled for 5 min. Proteins were
separated by 10% Novex Tris-glycine polyacrylamide gels (Invitrogen) and transferred to
nitrocellulose membranes (Invitrogen) in transfer buffer containing 20% methanol. The
membranes were blocked in 5% nonfat milk in Tris-buffered saline for 2 h, incubated in a 1 :
250 dilution of COX-1-specific monoclonal antibody (Cayman Chemical, Ann Arbor,
Michigan, USA) at 4°C overnight, and then washed in 0.05% Tris-buffered saline-Tween-20
four times. After incubation with a 1 : 2000 dilution of horseradish peroxidase-conjugated
bovine antimouse secondary antibody (Santa Cruz Biotechnology, Santa Cruz, California,
USA) and additional washing, COX-1 immunoreactive bands were detected by
chemiluminescence using the SuperSignal West Pico chemiluminescent substrate (Pierce,
Rockford, Illinois, USA).
To estimate differences in COX-1 expression across each preparation, densitometry was
completed after multiple immunoblots and mean fold differences in COX-1 immunoreactivity
were calculated for each variant relative to WT. The total amount of solubilized microsomal
protein used in all subsequent activity studies was normalized to COX-1 immunoreactivity
based on these calculations. Similar protein normalization methods have been utilized for the
functional characterization of nonsynonymous polymorphisms in other genes using a
baculovirus/insect cell expression system [7,19].
COX-1 enzymatic assay
COX-1 enzymatic activity was determined by measuring oxygen consumption at 37°C in an
oxygraph chamber using an YSI Model 53 oxygen monitor and electrode (YSI International,
Yellow Springs, Ohio, USA), as described [7,29-31]. The reaction buffer consisted of 100
mmol/l Tris (pH = 8.0) containing 500 μmol/l phenol. Solubilized microsomal protein from
the WT (3.4 mg of total protein) and eight variant (total protein amounts normalized to COX-1
immunoreactivity) preparations were reconstituted in reaction buffer with 10 μmol/l hematin
for 1 min on ice. Solubilized microsomal protein from uninfected Sf9 cells (3.4 mg of total
protein) was used as a negative control. Samples were then equilibrated in reaction buffer for
1 min at 37°C. Oxygen consumption was measured for 120 s following the addition of 100
μmol/l arachidonic acid (Cayman Chemical), and the rate of oxygen consumption was
calculated and expressed as μmol/lO2/min/mg microsomal protein. Three independent
experiments were completed, each in triplicate.
Inhibitor studies were completed with 0 (vehicle), 0.1, 1, 5, 10, and 25 μmol/l indomethacin
(Cayman Chemical) in the WT, R8W, P17L, G230S, and L237M preparations. Solubilized
microsomal proteins were reconstituted on ice for 10 min with hematin plus indomethacin,
each completed in triplicate, and oxygen consumption was measured using the experimental
conditions described above.
Statistical analysis
The rate of oxygen consumption was expressed relative to WT and averaged. Data are presented
as mean ± standard error of the mean, and were compared across COX-1 preparation by analysis
of variance. A post-hoc Dunnett's test assessed the presence of statistical differences between
each mutant relative to WT. A P-value of <0.05 was considered statistically significant.
To determine whether certain variants significantly influenced indomethacin-mediated
inhibition of COX-1, IC50 values were estimated. First, the data for each preparation were
plotted as percent activity relative to control (vehicle) versus natural log indomethacin
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concentration. The IC50 value for each was estimated according to the Hill equation by
nonlinear regression (WinNonlin, Pharsight Corporation, Mountain View, California, USA),
where Emax = 1.0, C = natural log indomethacin concentration, and the IC50 and γ (an
exponential term influencing the sigmoidal shape of the curve) values were estimated according
to the model's fit of the data:
Effect = Emax × 1 − ( CγCγ + IC50γ ) .
Triplicate values at each indomethacin concentration were simultaneously modeled for
estimation of a single IC50 value ( ± 95% confidence intervals) for each preparation. Inclusion
of a 1/Y2 weighting factor substantially improved the model's fit of the data according to the
Akaike information criterion value.
Results
Identification of PTGS1 variants
Sequencing the PTGS1 gene in 72 individuals of known ethnicity identified 44 variants (42
SNPs, one nucleotide insertion, and one nucleotide deletion). Evaluation of an additional 20
anonymous individuals of unknown ethnicity identified one additional SNP. Of these 45
variants, 14 were located in the 5′UTR, 12 were in exons, and 19 were in introns. Seven of the
12 exonic substitutions were nonsynonymous (R8W, R8P, P17L, R78W, K185T, L237M, and
V481I) and five were synonymous. The R8P and R78W variants have not been previously
reported. The R8P variant was identified in a single individual of African descent. The R78W
variant was identified in a single individual of unknown ethnicity. The R53H and G230S
variants reported in other populations [10,12] were not identified in this resequencing analysis;
however, we confirmed their existence at frequencies <1% in an independent African-
American population (n = 367) (data not shown). The minor allele frequencies of most
polymorphisms differed significantly across ethnicity, with the Asian sample demonstrating
the least genetic variation. The location minor allele frequencies, and other details for all 45
variants are summarized in Table 3. Given the magnitude of genetic diversity and admixture
across human populations, and the small number of chromosomes screened within each ethnic
group, the reported minor allele frequencies should be considered an approximation.
Linkage disequilibrium structure of the PTGS1 gene
The LD structure across PTGS1 is presented for each ethnicity (Fig. 1). A substantial degree
of LD was observed throughout the 5′UTR. This LD pattern specifically involved seven
polymorphisms (T-1749C, G-1598A, A-1202G, A-1201G, G-1006A, A-918G, and A-707G)
(Table 3) and was observed in both the European/Caucasian (D′ = 1.0, r2 = 0.73–1.0) and
African (D′ = 1.0, r2 = 1.0) samples, suggesting that these seven polymorphisms are on the
same haplotype. In European/ Caucasians, these 5′UTR polymorphisms were also in significant
LD with the P17L variant in exon 2. Interestingly, only two of the identified 5′UTR
polymorphisms (C-1160G and G-951A) are located in regions relatively conserved across
human, mouse, rat, dog, and chimp, suggesting that most are in regions that are not selectively
constrained. Our transcription factor binding site search suggests that the T-1749C
polymorphism could weaken a putative AML/RUNX1-binding site by changing the core motif
from TGTTGT to TGCTGT, the linked A-1202G and A-1201G polymorphisms could destroy
a putative NF-Y-binding site by changing the core NF-Y motif from CCAAT to CCGGT, and
the G-951A polymorphism could disrupt a putative NF-AT-binding site. In addition, the
G-1006A polymorphism could create a putative heat shock protein-binding site.
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Structural analysis of the COX-1 protein
Alignment of human, mouse, rat, and sheep COX-1 amino-acid sequences demonstrated that
the R78, G230, and L237 amino acids are conserved across each of these species (Fig. 2).
Interestingly, L237 is also conserved across all COX-2 protein sequences. The R53H, R78W,
K185T, G230S, L237M, and V481I variants were individually incorporated into the WT
human COX-1 model (Fig. 3). Substitution of a serine for glycine at residue 230 (G230S)
appears to significantly impact the structure of COX-1 (Fig. 4). First, glycine 230 is located
on a 310 helical turn, suggesting that this tight turn requires a glycine residue. The equivalent
residue in COX-2 is asparagine 231. Comparison of our model to murine COX-2 (PDB
accession 1CVU) [25,26] reveals that some of the backbone interactions in COX-2 are less
favorable than observed in COX-1, but these are offset through favorable interactions by the
asparagine 231 side chain to the backbone carbonyl of glutamine 208 and the side chain of
aspartic acid 229 (Fig. 4c). In our human COX-1 model, there is a single sterically compatible
rotamer conformation for serine 230 substitution, which can interact favorably with only one
hydrogen-bond acceptor (Fig. 4b). The minimum conformational change to avoid a negative
interaction is the rotation of aspartic acid 228 to a position within hydrogen-bonding distance
to arginine 332. This position, however, requires a displacement of tryptophan 138′, which
perturbs the dimer interface association, potentially influencing enzyme activity (Fig. 4d,
where ‘prime’ indicates a residue from the dimer associated molecule). Moreover, arginine
332 is solvent-accessible at the bottom of a narrow crevasse where arachidonic acid could form
hydrogen bonds and prevent stabilization of the proposed alternate conformation of aspartic
acid 228.
In the presence of the R53H, R78W, K185T, L237M, or V481I substitutions, common rotamer
conformations yielded reasonable accommodation of the substituted amino acid; however, in
certain cases potential minor alterations in structure that could influence enzyme activity were
noted. For instance, arginine 53 is in a solvent exposed region where substitution with histidine
(R53H) has no obvious effects; however, this substitution could have a minor influence on
glycosylation of asparagine 67 or the adjacent dimerization contact, both of which are
approximately about 10–11 Å away. The arginine 78 residue is at the membrane binding
surface, and, although conserved, a tryptophan substitution at this position (R78W) is also
favorable for membrane binding and unlikely to directly influence enzyme activity. The most
feasible functional role for arginine at this site would be to assist retrieval of arachidonic acid
into the active site. The lysine 185 residue is on a solvent exposed loop, distant from any
functional site likely to influence catalysis; however, this residue is in a positively charged
region with several arginines, which could serve some nonobvious function potentially altered
by a threonine substitution (K185T). The leucine 237 residue is likely involved in a
dimerization interaction, with significant contacts to sugars linked to asparagine 143 of the
related monomer. A methionine substitution (L237M) fits reasonably well into this site with
favorable hydrophobic interactions, but it is larger and more flexible. This mutation is predicted
to have a small effect on the dimerization interface. Moreover, oxidation of methionine could
conceivably impact the dimerization contact; however, it is unclear whether either of these
effects could significantly influence enzyme activity. The valine 481 residue is distant from
both the catalytic site and dimerization surface. As an isoleucine substitution (V481I) is
conservative, this mutation appears unlikely to influence enzyme activity.
Expression of the wild-type and variant COX-1 proteins
The COX-1 WT and mutant R8W, P17L, R53H, R78W, K185T, G230S, L237M, and V481I
proteins were expressed in Sf9 cells using a single promoter baculovirus system. The R8P
variant was not expressed as the R8W variant occurred at the same amino-acid position and
was more frequent. Expression was verified by immunoblotting, with a molecular mass of
approximately 70 kDa for the WT and mutant proteins (Fig. 5a). COX-1 expression was not
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observed in uninfected Sf9 cells. Consistent with previous studies of COX-1 expression in Sf9
cells [29,30], the relative amount of COX-1 in the solubilized microsomal fraction to the total
amount of protein was fairly low. Large-scale expression of each preparation, however,
generated enough COX-1 protein for functional characterization.
Densitometry analysis of multiple immunoblots demonstrated variability in the level of COX-1
immunoreactivity across preparations, with an approximate range of 0.3–1.4-fold difference
relative to WT. Immunoblots were repeated with varying amounts of solubilized microsomal
protein according to these densitometry results to normalize each preparation for COX-1
immunoreactivity, as presented in Fig. 5a. Such an approach normalized these preparation
differences in COX-1 expression and yielded approximately 0.9–1.1-fold difference in COX-1
immunoreactivity across each preparation relative to WT. Subsequently, equivalent amounts
of immunoreactive COX-1 for each preparation were included in the activity studies.
COX-1 enzymatic activity
The mean rate of oxygen consumption calculated for the WT COX-1 preparation was 19.7 ±
2.0 μmol/l O2/min/mg microsomal protein. The uninfected negative control demonstrated
undetectable oxygen consumption, suggesting detectable oxygen consumption in the COX-1
preparations was due to recombinant COX-1-mediated arachidonic acid metabolism. Pooled
analysis of three independent experiments demonstrated the R53H (35.0 ± 4.9%), R78W (36.1
± 3.9%), K185T (59.2 ± 6.4%), G230S (56.6 ± 3.5%), and L237M (51.0 ± 2.5%) variants had
significantly lower metabolic activity relative to WT COX-1 (100.0 ± 7.2%) (Fig. 5b, P < 0.05
of each variant versus WT). No significant differences in enzymatic activity were detected in
the R8W (103.8 ± 10.0%), P17L (113.3 ± 7.0%), and V481I (121.3 ± 10.2%) variants compared
with WT (Fig. 5b). Similar results were obtained in each of the three independent experiments.
Moreover, weight-adjusting the calculated oxygen consumption rates according to the mean
0.9–1.1-fold difference in COX-1 immuno-reactivity observed across each normalized
preparation did not significantly alter these results (data not shown).
Inhibition of COX-1 enzymatic activity
The sensitivity of the WT and R8W, P17L, G230S, and L237M variants to inhibition by
indomethacin, a non-selective COX inhibitor with greater potency for COX-1 than COX-2 in
recombinant systems, was evaluated. The R8W and P17L variants were selected as they are
the most frequent nonsynonymous polymorphisms. The G230S and L237M variants were
selected on the basis of our basal metabolic activity and modeling results reported above. The
effects of increasing indomethacin concentrations on metabolic activity for each preparation
relative to vehicle-incubated controls are presented (Fig. 6a-d). From these data, IC50 values
for each preparation were estimated (Table 4). The P17L and G230S variants demonstrated
significantly lower IC50 values than those of WT, suggesting presence of these mutations
significantly increase COX-1 sensitivity to inhibition by indomethacin. This increase in
sensitivity is evident in Fig. 6b and c, respectively. No significant differences in IC50 values
were observed with the R8W and L237M variants compared with the WT. The R8W variant
appeared more resistant to inhibition at lower indo-methacin concentrations relative to WT
(Fig. 6a); however, this effect was lost at higher indomethacin concentrations and the estimated
IC50 value was not statistically different from WT. The L237M variants appeared more
sensitive to inhibition at higher indo-methacin concentrations relative to WT (Fig. 6d);
however, the estimated IC50 value was not statistically different from WT.
To take into account basal COX-1 activity, we compared the rate of oxygen consumption in
each preparation after treatment with 25 μmol/l indomethacin relative to WT after treatment
with vehicle control (Fig. 6e). The P17L (13.8 ± 1.7%), G230S (4.1 ± 1.3%), and L237M (6.9
± 2.6%) variants each demonstrated significantly lower metabolic activity compared with WT
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(36.7 ± 0.5%) (P < 0.05 of each variant versus WT). Significant differences were not observed
with the R8W variant (29.4 ± 4.1%) compared with WT. These findings suggest that
combination of indomethacin treatment and the P17L, G230S, and L237M variants
significantly reduce COX-1 metabolic activity compared with indo-methacin treatment of WT
COX-1.
Discussion
COX-1 and COX-2-derived PGs play a vital role in the regulation of various biological
processes in humans, such that nonselective and selective NSAIDs are routinely administered
for the prevention and/or treatment of a variety of clinical conditions [1,4-6]. We and others
hypothesize that genetic variation in PTGS1 and PTGS2 may significantly modify disease risk
in humans and/or contribute to interindividual variability in the pharmaco-dynamic response
to NSAIDs. Although the functional relevance of genetic variants in PTGS2 has been evaluated
[7,8], functional characterization of human PTGS1 variants has not been as widely investigated.
To guide the design and interpretation of future genetic epidemiology and pharmacogenomic
studies, we sought to identify or confirm the existence of genetic polymorphisms in PTGS1,
characterize the LD structure, and evaluate the functional consequences of selected variants
in vitro.
We identified multiple variants in both coding and noncoding regions of human PTGS1 by
resequencing 92 healthy individuals. Twenty-four of the 45 variants had been previously
reported in the published literature [10-13] and/or publicly available databases (http://
www.ncbi.nlm.nih.gov/snp), and were present at comparable frequencies within each ethnic
group. Interestingly, seven of the 45 variants were nonsynonymous changes (R8W, R8P, P17L,
R78W, K185T, L237M, and V481I), most of which were present at low (≤ 6%) frequencies
in distinct ethnic groups. The previously reported R53H and G230S variants [10] were not
identified in the egSNP population, but we confirmed their existence at low frequencies in an
independent African-American population. Multiple polymorphisms in the PTGS1 5′UTR
were also identified, including seven (T-1749C, G-1598A, A-1202G, A-1201G, G-1006A,
A-918G, and A-707G) on the same haplotype in the European/Caucasian and African samples.
Moreover, these 5′UTR polymorphisms were also in near-complete LD with the P17L variant
in European/Caucasian, but not African individuals. The presence of LD between the
A-707G and P17L polymorphisms in Caucasians has been previously reported [11,12,14,32];
however, our analysis is the first to suggest that this LD pattern involves six additional
polymorphisms further upstream in the 5′UTR. A recent human investigation demonstrated
that presence of this variant haplotype was not associated with PTGS1 RNA expression in oral
mucosa [32]. Our preliminary sequence analysis suggests that certain 5′UTR variant alleles
may disrupt putative transcription factor binding sites. Further functional characterization of
these promoter polymorphisms via transcriptional activation and DNA-binding studies appears
necessary.
We expressed recombinant WT COX-1 and the R8W, P17L, R53H, R78W, K185T, G230S,
L237M, and V481I mutant proteins and evaluated basal COX-1 metabolic activity in vitro. As
summarized in Table 5, the R53H, R78W, K185T, G230S, and L237M variants demonstrated
significantly lower metabolic activity (35–60%) relative to WT COX-1; although, none
completely abolished activity, since as these did not occur at or in immediate proximity to
residues critical for substrate binding and/or enzyme activity such as arginine 120 or tyrosine
385 [33-36]. Our protein modeling results suggest the G230S variant may significantly alter
COX-1 protein structure. Our interpretation of these structural observations, in conjunction
with the observed functional effects, is that the G230S variant disrupts the active conformation
of COX-1 by shifting the dimer interface via D228 and W138′. This conformational change
could also influence catalysis more directly through an interaction between D228 and R332.
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R332 is a member of helix 6 [24], which also includes residues contributing to formation of
the active site. A shift in this helix could serve as the mechanism underlying the observed effect
on catalytic function.
Similar reductions in enzyme activity were also observed with the R53H, R78W, K185T, and
L237M variants, although their predicted impact on COX-1 structure were not as obvious. The
L237 residue is conserved across all known COX-1 and COX-2 species, and the L237M variant
presumably could influence catalytic activity through its predicted impact on dimerization;
however, the association between alterations in COX dimerization and metabolic activity has
not been well characterized. The mechanism underlying the alterations in activity observed
with the R53H, R78W, and K185T variants does not appear to be explained by our protein
modeling results. Recent COX-1 structure–function studies, however, suggest that several
amino-acid substitutions with modest influence on arachidonic acid binding to the COX-1
active site can alter the catalytic efficiency and metabolite profile of COX-1-mediated
arachidonic acid metabolism [36,37]. Perhaps these variants could reduce overall metabolic
efficiency by altering the interaction between arachidonic acid and the active site. Future
studies evaluating the mechanism underlying these functional effects appear necessary. No
significant changes in enzymatic activity were detected with the R8W, P17L, and V481I
variants relative to WT. The R8W and P17L variants occur at amino acids lying within the
COX-1 signal peptide sequence, which is posttranslationally cleaved [24,35], and would be
unlikely to significantly impact enzymatic activity. Our protein modeling suggests that the
V481I variant is also unlikely to significantly alter COX-1 structure or activity. Additional low
frequency nonsynonymous variants in PTGS1 have also been recently discovered (L15-L16del,
R108Q, I136V, K341R, R458Q) [10,13,16,38], however, their potential influence on COX-1
metabolic activity has not been investigated. Moreover, the in vivo functional consequences
of the R53H, R78W, K185T, G230S, L237M, and 5′UTR variants remain to be evaluated via
quantification of systemic (plasma, urine) and local (tissue-specific, cell-specific) PG
concentrations, particularly as the relative contribution of COX-2 to PG biosynthesis may also
be altered in individuals with certain PTGS1 polymorphisms. In vitro and in vivo functional
studies will substantially aid in the interpretation of genetic epidemiological studies evaluating
associations between PTGS1 polymorphisms and risk of diseases known to involve altered
COX-derived PG synthesis, such as cardiovascular and cerebrovascular disease, colorectal
cancer, and asthma [4,5].
Inhibition studies with indomethacin demonstrated that the P17L and G230S variants were
significantly more sensitive to indomethacin-mediated inhibition of COX-1 activity relative to
WT, as determined by estimation of IC50 values for each preparation (Table 5). As the P17L
variant resides within the COX-1 signal peptide sequence, the mechanism underlying the
observed alteration in indomethacin sensitivity is unclear. The estimated IC50 values for the
R8W and L237M variants were not significantly different from WT; however, COX-1
metabolic activity was significantly lower with the L237M variant relative to WT after
inhibition with indomethacin as the L237M variant also had significantly lower basal activity.
The estimated indomethacin IC50 value for the WT preparation in our study (8.37 μmol/l) was
higher than those previously reported with purified COX-1 preparations (approximately 1
μmol/l) [29,30]. This is likely due to our utilization of crude microsomal protein preparations.
Interestingly, a recent human study demonstrated that platelets isolated from Caucasian
individuals heterozygous for the P17L variant allele were significantly more sensitive to
aspirin-mediated inhibition of PGF2á production compared with WT individuals [12]. Our in-
vitro data with the P17L variant and indomethacin are consistent with these findings (Table
3), even though aspirin and indomethacin inhibit COX-1 activity via different mechanisms,
suggesting individuals carrying this variant may be significantly more sensitive to NSAID-
mediated inhibition of COX-1 activity and potentially more susceptible to adverse events such
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as gastrointestinal bleeding, renal dysfunction, and/or cardiovascular events [4]. Similar
associations may also exist with the G230S and L237M variants; although the population
impact of the P17L polymorphism may be more substantial as it is significantly more frequent
in both European/Caucasian and African populations. In contrast, human studies have also
suggested that the P17L variant may be associated with resistance to aspirin-mediated
inhibition of platelet aggregation [14] and aspirin-mediated reduction in risk of colorectal
polyps [16]. Importantly, these investigations were also conducted in Caucasian populations,
such that presence of the aforementioned PTGS1 5′UTR variant alleles, and not the P17L
variant allele, may be driving these observed interactions with aspirin therapy. Presence of the
P17L variant has also been associated with rofecoxib and celecoxib-mediated inhibition of
thromboxane formation in vivo [15]. The population evaluated in this investigation consisted
of Caucasian, African-American and Asian individuals. As the ethnicities of those carrying the
P17L variant allele were not reported, the potential contribution of PTGS1 5′UTR
polymorphisms could not be ascertained. Collectively, the mechanisms underlying these
conflicting in vitro and in vivo observations remain to be characterized; however, the relative
contribution of the P17L and 5′UTR polymorphisms may be an important determinant of
NSAID pharmacodynamics in humans. Additional human pharmacogenomic studies
evaluating potential associations between PTGS1 polymorphisms and NSAID
pharmacodynamics in both Caucasians and African-Americans, including risk of adverse
events, appear warranted.
We acknowledge that certain limitations exist in our analysis. First, utilization of a
nonmammalian expression system could significantly impact the expression and function of a
recombinant protein, particularly glycosylated proteins such as COX-1. The recombinant
COX-1, however, has been expressed in insect-cell systems previously, and has exhibited
similar posttranslational processing, glycosylation and activity profiles compared with native
COX-1 [29,30]. Second, we recognize the limitations related to evaluation of metabolic activity
at a single substrate concentration. The observed differences in the rate of oxygen consumption
in certain mutant preparations in comparison with the WT may be a reflection of reduced
metabolic capacity (decreased Vmax) and/or reduced substrate binding (increased Km).
Evaluation of metabolic activity across a range of substrate concentrations will ultimately be
necessary to more completely characterize the enzyme kinetics of each mutant relative to WT.
The quantification of oxygen consumption after addition of 100 μmol/l of arachidonic acid,
however, has been previously utilized to evaluate COX-1 metabolic activity in recombinant
systems [29,30]. Moreover, similar conditions have been employed for IC50 determinations of
multiple COX inhibitors, including indomethacin [29,30]. We recognize that indomethacin is
not utilized clinically as widely as aspirin, or for the same indication, and the clinical
applicability of our inhibition studies may not extend to all NSAIDs. Indomethacin, however,
has demonstrated greater potency for inhibition of COX-1 than COX-2 and has been widely
studied in this recombinant in vitro system under these experimental conditions [29,30].
Consequently, we felt it was a more appropriate inhibitor for the initial characterization of
selected COX-1 variants.
In summary, the R53H, R78W, K185T, G230S, and L237M variants in PTGS1 demonstrated
significantly lower basal metabolic activity in vitro relative to WT COX-1, suggesting
individuals carrying these variant alleles may have significantly altered PG biosynthesis in
vivo. In addition, the P17L and G230S variants were significantly more sensitive to
indomethacin-mediated inhibition of COX-1 activity relative to WT, suggesting individuals
carrying these variant alleles may be more susceptible to NSAID-associated adverse events.
Future studies confirming the in vivo relevance of these variants, including their influence on
disease susceptibility and NSAID pharmacodynamics, are warranted.
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Pairwise estimates of linkage disequilibrium (LD) between each PTGS1 polymorphism are
plotted for the (a) African, (b) European/Caucasian, and (c) Asian ethnic groups using
Haploview 3.2. Each polymorphism is numbered according to its position in the PTGS1 gene
as presented in Table 3. Black squares indicate complete LD (r2 = 1.0), white squares indicate
zero LD (r2 = 0.0), and increasing intensity of grey indicates increasing degrees of LD.
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Alignment of the human (Genbank accession number P23219), mouse (AAH05573), rat
(NP_058739), and sheep (P05979) COX-1 amino-acid sequences using the ClustalW program.
Amino-acid locations of the eight evaluated nonsynonymous variants are highlighted.
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Overview of the COX-1 dimer and the R53H, R78W, K185T, G230S, L237M, and V481I
variants, with (a) a top view of the dimer complex and (b) a side view of one monomer facing
the dimerization surface. Mutations are illustrated with space-filling atoms. The heme group
is shown in maroon, and arachidonic acid is shown in yellow. Sugars are shown in cyan, with
two sugars per glycosylation site.
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Structural characterization of the G230S variant. (a) The vicinity of G230 in the model of wild-
type COX-1. The position of D228 is stabilized by a hydrogen bond to the backbone nitrogen
of G230. (b) The G230S substitution allows for only one rotamer position without significant
structural changes. (c) The corresponding site in human COX-2 has an N231 in a similar
position to the modeled S230 substitution; however, N231 also provides several interactions
that help stabilize the observed conformation. (d) In COX-1, S230 destabilizes the observed
conformation, which could be avoided by a rotation of D228 towards R332, which also requires
a shift in the dimer interaction with W138′.
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(a) Representative immunoblot of solubilized microsomes containing recombinant wild-type
(WT) and eight variant COX-1 proteins. The amount of solubilized microsomal protein loaded
per lane for each preparation was normalized to COX-1 immunoreactivity based on previous
immunoblots. The WT lane contains 34 μg of microsomal protein. Lane 1 contains COX-1
ovine protein standard (Cayman Chemical, 1 μg) as a positive control. Lane 11 contains
solubilized microsomes made from uninfected Sf9 cells (34 μg) as a negative control. (b) Mean
± SEM rate of oxygen consumption for each of the eight variant COX-1 preparations relative
to WT. Solubilized microsomal protein from uninfected Sf9 cells were used as a negative
control. The data presented are pooled from three independent experiments, each completed
in triplicate. The rate of oxygen consumption was significantly associated with the COX-1
microsomal preparation (analysis of variance: P < 0.001, r2 = 0.78). *P < 0.05 versus WT by
a post-hoc Dunnett's test.
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Inhibition of COX-1-mediated arachidonic acid metabolism by increasing concentrations of
indomethacin in the (a) R8W, (b) P17L, (c) G230S, and (d) L237M variants compared with
wild-type (WT). Values represent the mean ± SEM rate of oxygen consumption calculated at
each indomethacin concentration (0.1, 1, 5, 10, and 25 μmol/l) relative to the rate of oxygen
consumption detected with vehicle control for each preparation. Each data point includes three
independent measurements. (e) Mean ± SEM rate of oxygen consumption for the WT and
R8W, P17L, G230S, and L237M variants after incubation with 25 μmol/l indomethacin relative
to the rate of oxygen consumption detected after incubation with vehicle control in the WT
preparation. Each data point includes three independent measurements. The rate of oxygen
consumption after incubation with 25 μmol/l indomethacin was significantly associated with
the COX-1 preparation (analysis of variance: P < 0.001, r2 = 0.93). *P < 0.05 versus WT by
a post-hoc Dunnett's test.
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Table 1
Oligonucleotide primers used for PCR amplification of PTGS1
PTGS1 Region Forward primer sequence Reverse primer sequence
Promoter 1 5′-GAAGGCACAGGGGCTTCCTAGA-3′ 5′-AGTGGGGAGAAGGTAGATGAGAG-3′
Promoter 2 5′-TGTCCTCAGCACCTTTCTTCCCCTA-3′ 5′-CCCTCCCCCATTCTCACCCAAG-3′
Promoter 3 5′-GCATGGGAACACCTTGGGTGAGAATG-3′ 5′-CAGACTCCACAGCTTACTGGCCGTG-3′
Promoter 4 5′-GCCTTCCGATAACTGAGCACCTAC-3′ 5′-GGCTGCCCGCTTACTTCCTCTGC-3′
Promoter 5 5′-CAGGCCAGGCTGGACTGCCCCATTTCT-3′ 5′-CAGGAGGCCAAGAAAATTCC-3′
Exons 1 and 2 5′-CACGCACAGGAGCCTGCACTCTGCGTCC-3′ 5′-GAAAGGAGGGGGTTGAAACCAGGC-3′
Exon 3 5′-CAGGGAGTGAGGGTGGACCAAGAGCG-3′ 5′-GTCAGGATGGGTGGTTTATGTTCA-3′
Exon 4 5′-GTCTCTGTCATGTGTCATTGC-3′ 5′-GGCACAGAGGGCAGAATACGAGTG-3′
Exon 5 5′-GAGCTGGGGGTGGAAACACCCTTGTCA-3′ 5′-TTCCCAAAGAGAAGAACTGAGCA-3′
Exon 6 5′-CTTGACTCAGGGCAAGGGAGTTCAT-3′ 5′-GGTGCCGGCCCACTGTCGAT-3′
Exon 7 5′-GGAAGAAGCAGTTGCCAGATGC-3′ 5′-CTGTCGCTCCTGGCACAAGCCT-3′
Exon 8 5′-GCTGAGGGGAACTGGCAGCTTGGA-3′ 5′-GCAGGAAGGTAGATACATGCAG-3′
Exon 9 5′-CAAGCTGGGCATCTAAATCACTGT-3′ 5′-GCTGTCGTATGACTGCCATCACT-3′
Exon 10 5′-GACTCCCACTGGAAGCTCTTGTC-3′ 5′-TACACATTGCCGCATGTATTGT-3′
Exon 11 5′-CCCAGAAAAAGGTGGACCTGGAA-3′ 5′-TGGAATGACAAGCACAAAGCTC-3′
Sequencea 5′-GTTTTCCCAGTCACGACG-3′ 5′-AGGAAACAGCTATGACCAT-3′
a
The 5′ binding site sequence for the forward and reverse energy transfer DNA sequencing primers.













Lee et al. Page 22
Table 2
Primers used for the site-directed mutagenesis of human COX-1
Mutation Sequences of forward and reverse primersa
Arg8Trp (R8W) (F) 5′-CCATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCC-3′
(R) 5′-GGAGCAGGAACAGCAAGAACCAGAGCAAGAGACTCCGGCTCATGG-3′
Pro17Leu (P17L) (F) 5′-GCTGTTCCTGCTCCTGCTCCTGCCGCTCCCCGTCCTGCTCG-3′
(R) 5′-CGAGCAGGACGGGGAGCGGCAGGAGCAGGAGCAGGAACAGC-3′
Arg53His (R53H) (F) 5′-CCGCTTCGGCCTTGACCACTACCAGTGTGACTGC-3′
(R) 5′-GCAGTCACACTGGTAGTGGTCAAGGCCGAAGCGG-3′
Arg78Trp (R78W) (F) 5′-GCCTGTGGACCTGGCTCTGGAATTCACTGCGGCCC-3′
(R) 5′-GGGCCGCAGTGAATTCCAGAGCCAGGTCCACAGGC-3′
Lys185Thr (K185 T) (F) 5′-GCTTCCTGCTCAGGAGGACGTTCATACCTGACCCCC-3′
(R) 5′-GGGGGTCAGGTATGAACGTCCTCCTGAGCAGGAAGC-3′
Gly230Ser (G230S) (F) 5′-GGGCCATGGGGTAGACCTCAGCCACATTTATGGAGAC-3′
(R) 5′-GTCTCCATAAATGTGGCTGAGGTCTACCCCATGGCCC-3′
Leu237Met (L237M) (F) 5′-CGGCCACATTTATGGAGACAATATGGAGCGTCAGTATCAACTGCGGC-3′
(R) 5′-GCCGCAGTTGATACTGACGCTCCATATTGTCTCCATAAATGTGGCCG-3′
Val481Ile (V481I) (F) 5′-CCTCCTTCCAGGAGCTCATAGGAGAGAAGGAGATGGC-3′
(R) 5′-GCCATCTCCTTCTCTCCTATGAGCTCCTGGAAGGAGG-3′
a
Primers were PAGE-purified (Invitrogen). Bold/underlined bases indicate the mutated nucleotides. The R8P mutant was not expressed.
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Table 4
Estimated IC50 values for indomethacin with WT COX-1 and the R8W, P17L, G230S, and L237M variants









P-value < 0.05 versus WT.
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